136 related articles for article (PubMed ID: 23482770)
21. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
22. [Progress of cancer stem cells of solid tumor].
Ni XG; Zhao P
Ai Zheng; 2006 Jun; 25(6):775-8. PubMed ID: 16764780
[TBL] [Abstract][Full Text] [Related]
23. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
[TBL] [Abstract][Full Text] [Related]
26. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
28. Progenitor stem cell marker expression by pulmonary carcinomas.
Moreira AL; Gonen M; Rekhtman N; Downey RJ
Mod Pathol; 2010 Jun; 23(6):889-95. PubMed ID: 20305619
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
30. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
31. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer.
Sienel W; Dango S; Woelfle U; Morresi-Hauf A; Wagener C; Brümmer J; Mutschler W; Passlick B; Pantel K
Clin Cancer Res; 2003 Jun; 9(6):2260-6. PubMed ID: 12796394
[TBL] [Abstract][Full Text] [Related]
32. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
Huang M; Zhu H; Feng J; Ni S; Huang J
Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
[TBL] [Abstract][Full Text] [Related]
33. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
35. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.
Chen YC; Hsu HS; Chen YW; Tsai TH; How CK; Wang CY; Hung SC; Chang YL; Tsai ML; Lee YY; Ku HH; Chiou SH
PLoS One; 2008 Jul; 3(7):e2637. PubMed ID: 18612434
[TBL] [Abstract][Full Text] [Related]
36. [Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma].
Zhang HZ; Wei YP; Wang M; Wu C; Yang YQ; Chen J; Cao YK
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):696-9. PubMed ID: 17545092
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis.
Xu YH; Zhang GB; Wang JM; Hu HC
Saudi Med J; 2010 Sep; 31(9):980-6. PubMed ID: 20844808
[TBL] [Abstract][Full Text] [Related]
38. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
40. Preliminary analysis of stem cell-like cells in human neuroblastoma.
Xing LL; Sha YL; Wu YM; Hu JM; Zhang M; Lv F
World J Pediatr; 2015 Feb; 11(1):54-60. PubMed ID: 25431041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
